Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone650-352-4150
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees57
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Forty Seven (NASDAQ:FTSV) Frequently Asked Questions
What is Forty Seven's stock symbol?
Forty Seven trades on the NASDAQ under the ticker symbol "FTSV."
How were Forty Seven's earnings last quarter?
Forty Seven Inc (NASDAQ:FTSV) released its earnings results on Tuesday, August, 13th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.69) by $0.05. View Forty Seven's Earnings History.
When is Forty Seven's next earnings date?
What price target have analysts set for FTSV?
7 Wall Street analysts have issued 1 year target prices for Forty Seven's shares. Their predictions range from $18.00 to $36.00. On average, they anticipate Forty Seven's share price to reach $25.50 in the next year. This suggests a possible upside of 317.3% from the stock's current price. View Analyst Price Targets for Forty Seven.
What is the consensus analysts' recommendation for Forty Seven?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Forty Seven in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Forty Seven.
What are Wall Street analysts saying about Forty Seven stock?
Here are some recent quotes from research analysts about Forty Seven stock:
- 1. According to Zacks Investment Research, "Forty Seven, Inc. is a clinical-stage immuno-oncology company. It focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer. The company's product candidate consists of 5F9, is an IgG4 monoclonal antibody against CD47 which is designed to interfere with recognition of CD47 by the SIRP? receptor on macrophages. Forty Seven, Inc. is based in CA, United States. " (10/16/2019)
- 2. Mizuho analysts commented, "We initiate coverage of FTSV with a Buy rating and $18 PT. We like the speed- to-market program for 5F9 (pivotal readout by 4Q20). We also like the pursuit of a novel mechanism in immuno-oncology, innate immunity via CD47. FTSV has cash into 2021 and readouts that should serve as valuation inflection points." (9/11/2019)
Has Forty Seven been receiving favorable news coverage?
News coverage about FTSV stock has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Forty Seven earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Forty Seven.
Who are some of Forty Seven's key competitors?
Some companies that are related to Forty Seven include ArQule (ARQL), Dicerna Pharmaceuticals (DRNA), Gossamer Bio (GOSS), Theravance Biopharma (TBPH), Epizyme (EPZM), Amphastar Pharmaceuticals (AMPH), TherapeuticsMD (TXMD), Odonate Therapeutics (ODT), AnaptysBio (ANAB), Spectrum Pharmaceuticals (SPPI), Y-mAbs Therapeutics (YMAB), ANI Pharmaceuticals (ANIP), Phibro Animal Health (PAHC), ZEALAND PHARMA/S (ZEAL) and Eagle Pharmaceuticals (EGRX).
What other stocks do shareholders of Forty Seven own?
Who are Forty Seven's key executives?
Forty Seven's management team includes the folowing people:
- Dr. Mark A. McCamish, Pres, CEO & Director (Age 66)
- Dr. Craig S. Gibbs, Chief Bus. Officer (Age 56)
- Dr. Chris H. Takimoto M.D., Ph.D., Chief Medical Officer (Age 60)
- Mr. Mark Chao, Founder & VP of Clinical Devel.
- Mr. Jens-Peter Volkmer, Founder and VP of Research & Early Devel.
When did Forty Seven IPO?
(FTSV) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity, BTIG and Oppenheimer were co-managers.
How do I buy shares of Forty Seven?
Shares of FTSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Forty Seven's stock price today?
One share of FTSV stock can currently be purchased for approximately $6.11.
How big of a company is Forty Seven?
Forty Seven has a market capitalization of $257.96 million. The company earns $-70,370,000.00 in net income (profit) each year or ($3.75) on an earnings per share basis. Forty Seven employs 57 workers across the globe.View Additional Information About Forty Seven.
What is Forty Seven's official website?
How can I contact Forty Seven?
Forty Seven's mailing address is 1490 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025. The company can be reached via phone at 650-352-4150 or via email at [email protected]
MarketBeat Community Rating for Forty Seven (NASDAQ FTSV)
MarketBeat's community ratings are surveys of what our community members think about Forty Seven and other stocks. Vote "Outperform" if you believe FTSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FTSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
